Evidence map›Paper›PMID 28205574›Full record

ReviewNature reviews. Disease primers2017

Neuropathic pain.

Luana Colloca, Taylor Ludman, Didier Bouhassira, Ralf Baron, Anthony H Dickenson, David Yarnitsky, Roy Freeman, Andrea Truini, Nadine Attal, Nanna B Finnerup and 5 more

5 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Disease primers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 1,087 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,087citing papers in PubMed, 10 pooled it
76.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04550884 unknown statusnot on this mapstarted 2020, after this paper: background citation

Neuropathic Foot and Ankle in Rheumatoid Arthritis : Ultrasound and Nerve Conduction Study

TypeobservationalSponsorAssiut UniversityRan2020 to 2023Enrolled80ConditionsRheumatoid ArthritisArmsneuromascular ultrasound
NCT04808531 phase3unknown statusnot on this mapstarted 2023, after this paper: background citation

NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial

TypeinterventionalSponsorMedlab ClinicalRan2023 to 2024Enrolled360ConditionsCancer Related PainArmsNanaBis™, Oxycodone CR, Placebo Spray, Placebo Tablet, Oxycodone IR
NCT05411900 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome: a Multicenter, Randomized, Doubleblind, Placebo-controlled Study

TypeinterventionalSponsorFrancesco BonoRan2022 to 2023Enrolled164ConditionsCarpal Tunnel Syndrome, Neurogenic Inflammation, Pain, Drug UseArmsBoNT-A, Placebo
NCT05427058 narecruitingnot on this mapstarted 2024, after this paper: background citation

Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety

TypeinterventionalSponsorUniversity of BrawijayaRan2024 to 2026Enrolled36ConditionsCervical Cancer, Endometrial CancerArmsSuperior Hypogastric Plexus Block, Ganglion Impar Block
NCT06030297 nacompletednot on this mapstarted 2023, after this paper: background citation

Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.

TypeinterventionalSponsorUniversity of UtahRan2023 to 2026Enrolled75ConditionsPeripheral NeuropathyArmsDiode Laser fiber type Selective Stimulator, ZTlido 1.8 % Topical System, PeriCam PSI NR, Medoc Quantitative Sensory Testing, Inactive Topical System
3 · Its place in the literature

Who cites it

1,087 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,953 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Neuromodulation of the central nervous system for facial pain.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Article
  14. Glial cells in neuropathic pain.Physiological reviews · 2026
    Review
  15. Observational
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

1,027 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 9 countries.

Luana CollocaDepartment of Pain and Translational Symptom Science, School of Nursing and Department of Anesthesiology School of Medicine, University of Maryland, 655 West Lombard Street, 21201 Baltimore, Maryland, USA.
Taylor LudmanDepartment of Pain and Translational Symptom Science, School of Nursing and Department of Anesthesiology School of Medicine, University of Maryland, 655 West Lombard Street, 21201 Baltimore, Maryland, USA.
Didier BouhassiraINSERM, Unit 987, Ambroise Paré Hospital, UVSQ, Boulogne Billancourt, France.
Ralf BaronDepartment of Neurology, Division of Neurological Pain Research and Therapy, Klinik fur Neurologie Christian-Albrechts-Universität Kiel, Kiel, Germany.
Anthony H DickensonDepartment of Neuroscience, Physiology and Pharmacology, University College London, London, UK.
David YarnitskyDepartment of Neurology, Rambam Health Care Campus, Technion Faculty of Medicine, Haifa, Israel.
Roy FreemanDepartment of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Andrea TruiniDepartment of Neurology and Psychiatry, Sapienza University, Rome, Italy.
Nadine AttalPain Evaluation and Treatment Centre of Hôpital Ambroise Paré, Paris, France.
Nanna B FinnerupDepartment of Clinical Medicine - The Danish Pain Research Center, Aarhus University, Aarhus, Denmark.
Christopher EcclestonCentre for Pain Research, University of Bath, Bath, UK.
Eija KalsoDivision of Pain Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
David L BennettNuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.
Robert H DworkinDepartment of Anesthesiology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA.
Srinivasa N RajaDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Hôpital Ambroise-Paré · FRUniversity of Maryland, Baltimore · USDanish Pain Research Center · DKHarvard University · USJohns Hopkins Medicine · USKiel University · DERambam Health Care Campus · ILSapienza University of Rome · ITUniversity College London · GBUniversity of Bath · GBUniversity of Helsinki · FIUniversity of Oxford · GBUniversity of Rochester · US

Funding

INJURY-INDUCES PAIN-- CHEMICAL MODULATION OF NOCICEPTORSR01NS026363 · NINDS · JOHNS HOPKINS UNIVERSITY · PI RAJA, SRINIVASA N. · 1989 to 2021
$6.8M
Chronic orofacial pain: genetics, cognitive-emotional factors, and endogenous modulatory systemsR01DE025946 · NIDCR · UNIVERSITY OF MARYLAND BALTIMORE · PI COLLOCA, LUANA · 2016 to 2019
$2.1M
NIDCR NIH HHS R01 DE025946NINDS NIH HHS R01 NS026363Wellcome Trust 202747/Z/16/Z
6 · The paper itself

Abstract

Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7-10% of the general population. Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy. Indeed, imbalances between excitatory and inhibitory somatosensory signalling, alterations in ion channels and variability in the way that pain messages are modulated in the central nervous system all have been implicated in neuropathic pain. The burden of chronic neuropathic pain seems to be related to the complexity of neuropathic symptoms, poor outcomes and difficult treatment decisions. Importantly, quality of life is impaired in patients with neuropathic pain owing to increased drug prescriptions and visits to health care providers, as well as the morbidity from the pain itself and the inciting disease. Despite challenges, progress in the understanding of the pathophysiology of neuropathic pain is spurring the development of new diagnostic procedures and personalized interventions, which emphasize the need for a multidisciplinary approach to the management of neuropathic pain.

Indexed as

AminesAnalgesicsCyclohexanecarboxylic AcidsDrug Therapy, CombinationGabapentingamma-Aminobutyric AcidHumansLidocaineNarcoticsNeoplasmsNeuralgiaNociceptive PainPain ManagementPregabalinQuality of LifeTramadolAminesAnalgesicsCyclohexanecarboxylic AcidsGabapentingamma-Aminobutyric AcidLidocaineNarcoticsPregabalinTramadolVoltage-Gated Sodium Channel Blockers

Identifiers

PMID28205574
PMCPMC5371025
OpenAlexW4211119836

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.